Skip to main content
Guidance

National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)

This protocol is for the administration of COVID-19 mRNA vaccine BNT162b2 to individuals in accordance with the national COVID-19 vaccination programme.

Updates to this page

From:
UK Health Security Agency
Published:
18 December 2020
Last updated:
20 November 2021
Show all updates

  1. Added version 06.00 – details of changes on page 5.

  2. Added version 05.00 (details of changes on page 4).

  3. Added version 04.00 (details of changes on page 4).

  4. Added version 3 (details of changes on page 3).

  5. Added revised protocol - see details of changes on page 2.

  6. Updated to correct mg to micrograms in dose section.

  7. First published.

This publication was withdrawn on

No Regulation 174 authorised COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) supplies remain in the system for administration as part of the National COVID-19 vaccination programme.

See the National protocol for Comirnaty 30microgram/dose COVID-19 mRNA vaccine for the use of product supplied under Conditional Marketing Authorisation.

Applies to England

Documents

[Withdrawn] National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)

Ref: UKHSA gateway number GOV-10471

MS Word Document, 235 KB

This file may not be suitable for users of assistive technology.

Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This protocol is for the administration of coronavirus (COVID-19) mRNA Vaccine BNT162b2 by appropriately trained persons.

National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) v06.00 is valid from 20 November 2021 to 31 March 2022.

Sign up for emails or print this page